摘要
目的研究埃克替尼单一用药及联合重组人血管内皮抑素(YH-16)治疗EGFR阳性晚期非小细胞肺癌临床疗效及相关毒副反应。方法EGFR阳性的非小细胞肺腺癌46例晚期随机分为对照组和观察组,每组23例。对照组均服用埃克替尼250mg/d,观察组患者联合应用重组人血管内皮抑制素(静脉给药),直到病变进展或其他原因停药。治疗满2个周期(21d为1个周期)。比较2组疾病控制率与总缓解率、生活质量及不良反应发生情况。结果对照组患者疾病控制率及总缓解率明显低于观察组(P<0.05)。干预后观察组患者心理因子、生理因子、环境因子、社会因子及中评分均明显高于对照组(P<0.05)。2组患者皮疹、腹泻、恶心、转氨酶升高等不良反应发生率比较差异无统计学意义(P>0.05)。结论埃克替尼与重组人血管内皮抑制素联合用药较埃克替尼单用可明显提高EGFR阳性晚期非小细胞肺癌患者疾病控制率及总缓解率、提高患者生活水平、不增加不良反应发生率。
Objective To observe the clinical curative effects and toxicity of simple icotinib or icotinib combined with endostar(recombinant human endostatin,YH-16) in the treatment of advanced non-small cell lung cancer(NSCLC) with positive EGFR.Methods A total of 46 patients with advanced EGFR-positive non-small cell lung adenocarcinoma,who were treated in our hospital from May 2015 to December 2017,were randomly divided into observation group and control group,with23 cases in each group.The patients in control group were treated by icotinib 250 mg/d,however,the patients in observation group,on the basis of control group,were given endostar by intravenous medication until the disease progressed or drug discontinuance due to other reasons,with a treatment course of 21 days for two cycles.The disease control rate,total remission rate,life quality and incidence of adverse reactions were observed and compared between the two groups.Results The disease control rate and total remission rate in control group were 47.82% and 30.43%,respectively,which were significantly lower than those in observation group(78.26% and 60.87%,P<0.05).After treatment the psychological factors,physiological factors,environmental factors,social factors and median scores in observation group were significantly higher than those in control group(P<0.05).Moreover there were no significant differences in the incidence rates of adverse reactions including rash,diarrhea,nausea and elevated transaminase between the two groups(P > 0.05).Conclusion As comparedwith simple icotinib,the icotinib combined with endostar can significantly improve the disease control rate and total remission rate of EGFR-positive patients with advanced non-small cell lung cancer,improve the life quality of patients,without increasing the incidence rate of adverse reactions.
作者
杨艳
张明晖
马艳青
张晓洁
魏海波
YANG Yan;ZHANG Minghui;MA Yanqing(Department of Oncology,Chifeng Municipal Hospital,InneRMongolia,Chifeng 024000,China)
出处
《河北医药》
CAS
2019年第14期2199-2201,共3页
Hebei Medical Journal
